IMTX
Immatics N.V. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +10.0% ·
share flow -30.0% ·
net new positions +9.1%
— formula
Ownership fragmentation — more holders, smaller aggregate stake
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 35 | 0 | 11.76M | $118.95M | +4 | −4 |
| Q1 2026 | 35 | +3 | 20.34M | $199.85M | +5 | −2 |
| Q4 2025 | 31 | 0 | 13.12M | $137.78M | — | — |
| Q3 2025 | 11 | +1 | 6.87M | $58.55M | +2 | −1 |
| Q2 2025 | 7 | -1 | 7.51M | $36.14M | — | −1 |
| Q1 2025 | 7 | -3 | 10.10M | $41.98M | — | −3 |
| Q4 2024 | 10 | +1 | 14.90M | $100.53M | +2 | −1 |
| Q3 2024 | 8 | 0 | 16.54M | $184.94M | +1 | −1 |
| Q2 2024 | 8 | — | 15.53M | $176.70M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Morgan Stanley ✦ | 2.21M | — | $18.79M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Morgan Stanley ✦ | 2.21M | — | $18.79M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Morgan Stanley ✦ | 2.21M | — | $18.79M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Morgan Stanley ✦ | 2.21M | — | $18.79M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Wellington Management ✦ | 1.51M | -71.6% | $12.88M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 6 | Wellington Management ✦ | 1.51M | -71.6% | $12.88M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 7 | Wellington Management ✦ | 1.51M | -71.6% | $12.88M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 8 | T. Rowe Price ✦ | 724.81K | New | $6.18M | 0.0% | New | 1 | SEC ↗ |
| 9 | Millennium Management ✦ | 721.87K | +4991.1% | $6.15M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 10 | Citadel Advisors ✦ | 603.15K | -31.4% | $5.14M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 11 | Citadel Advisors ✦ | 603.15K | -31.4% | $5.14M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 12 | JPMorgan Chase ✦ | 271.91K | — | $2.32M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | JPMorgan Chase ✦ | 271.91K | — | $2.32M | 0.0% | n/c | 1 | SEC ↗ |
| 14 | BlackRock ✦ (passive) | 236.52K | -2.0% | $2.02M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 15 | BlackRock ✦ (passive) | 236.52K | -2.0% | $2.02M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 16 | BlackRock ✦ (passive) | 236.52K | -2.0% | $2.02M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 17 | State Street Global Advisors ✦ (passive) | 218.50K | +19.6% | $1.86M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 18 | Goldman Sachs Group ✦ | 190.76K | — | $1.63M | 0.0% | n/c | 1 | SEC ↗ |
| 19 | Point72 Asset Management ✦ | 118.19K | New | $1.01M | 0.0% | New | 1 | SEC ↗ |
| 20 | Geode Capital Management ✦ (passive) | 68.73K | 0.0% | $585,596 | 0.0% | Held | 6 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| T. Rowe Price | $6.18M | 0.0% |
| Point72 Asset Management | $1.01M | 0.0% |
Exited
| D. E. Shaw & Co. | $63,916 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 82 holders, 108.05M shares, $842.81M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.